A recent report from Statista predicts that the market for prescription drugs is set to rise by more than $1 trillion this year, up by more of a third from 2016.
It estimates that the annual sales of the most popular drugs sold through pharmacies in the US will surpass $4.2 trillion, which is a $300 billion jump.
The report is based on sales data from data aggregator Statista, which aggregates data on all the drugs that doctors prescribe.
This is important because doctors aren’t allowed to prescribe their own drugs, which means they can’t control the prices of the drugs.
That means, as a result, the market is set up to grow dramatically.
The market is now projected to surpass $7.4 trillion in 2019, a staggering increase of more than 20 percent from last year.
Statista says that this is due to the rise in generic competition.
The drugs in the top 10 of its top 100 generic drug list account for less than a quarter of the market, but it’s estimated that as the top generic drug maker expands its portfolio, it will be able to drive up the prices and sales of many of its competitors.
The top 10 generic drug makers are: Amgen, Cephalon, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, and UnitedHealth.
In total, the top 100 generics in the country accounted for more than half of all generic sales in 2019.
The number of people using the drugs, or prescriptions, on the riseThe most important drug of the next decade, it seems, is a generic version of the drug called Avandia, which has a much better patent than the original.
That could help drive down prices.
According to Statista’s estimates, Avandias price will fall by up to $50 a pill, compared to $10 a pill for the original generic.
And while some people will still be willing to pay more for the Avandiacs generic version, it’s expected that the price will drop by as much as 25 percent from the original $50 to $20 a pill.
That will mean that some people who might not normally take these drugs are going to start getting them.
The top generic drugs on the market are: Cepham, GlaxoSmithKline, and AstraZeneca.
The company that made the first generic of Avandiamax, Sanofi, is now also making generic versions of the medication.
